Table of Contents

company-logo

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics Dividend Announcement

• Kyverna Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Kyverna Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Kyverna Therapeutics Dividend History

Kyverna Therapeutics Dividend Yield

Kyverna Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kyverna Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Kyverna Therapeutics Financial Ratios

P/E ratio-2.60
PEG ratio-0.03
P/B ratio0.72
ROE-81.21%
Payout ratio0.00%
Current ratio14.86
Quick ratio14.86
Cash Ratio5.61

Kyverna Therapeutics Dividend FAQ

Does Kyverna Therapeutics stock pay dividends?
Kyverna Therapeutics does not currently pay dividends to its shareholders.
Has Kyverna Therapeutics ever paid a dividend?
No, Kyverna Therapeutics has no a history of paying dividends to its shareholders. Kyverna Therapeutics is not known for its dividend payments.
Why doesn't Kyverna Therapeutics pay dividends?
There are several potential reasons why Kyverna Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Kyverna Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Kyverna Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Kyverna Therapeutics a dividend aristocrat?
Kyverna Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Kyverna Therapeutics a dividend king?
Kyverna Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Kyverna Therapeutics a dividend stock?
No, Kyverna Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Kyverna Therapeutics stocks?
To buy Kyverna Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Kyverna Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.